Does Ali Behbahani’s Form 4 show any BDTX share sales?

The Form 4 does not report any sales of Black Diamond Therapeutics shares by Ali Behbahani. It shows a stock grant of 8,961 shares as compensation and indirect holdings reported through New Enterprise Associates 16, L.P., with certain beneficial ownership disclaimed.

Ali Behbahani of Black Diamond (NASDAQ: BDTX) receives 8,961-share award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.

Black Diamond Therapeutics director Ali Behbahani received a grant of 8,961 shares of common stock at $1.66 per share. These shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in which he elected stock instead of cash for annual board service.

After this award, Behbahani directly holds 102,529 shares of common stock. Separately, 4,448,757 shares are reported as indirectly held by New Enterprise Associates 16, L.P., where he is affiliated through general partner entities. He disclaims beneficial ownership of portions of those indirect holdings in which he has no pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Behbahani Ali

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,961	$1.66	$15K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 102,529 shares (Direct, null); Common Stock — 4,448,757 shares (Indirect, See Note 3)

Footnotes (1)

These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

Key Figures

Director stock grant: 8,961 shares Grant reference price: $1.66 per share Direct holdings after grant: 102,529 shares +1 more

4 metrics

Director stock grant 8,961 shares Common Stock grant for annual non-employee director services

Grant reference price $1.66 per share Closing market price on June 18, 2026

Direct holdings after grant 102,529 shares Common Stock held directly by Ali Behbahani

Indirect holdings via NEA 16 4,448,757 shares Common Stock held by New Enterprise Associates 16, L.P.

Key Terms

Sixth Amended and Restated Non-Employee Director Compensation Policy, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, beneficial ownership

4 terms

Sixth Amended and Restated Non-Employee Director Compensation Policy financial

"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy"

pecuniary interest financial

"the Reporting Person has no pecuniary interest"

Section 16 of the Securities Exchange Act of 1934 regulatory

"disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership within the meaning of Section 16"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:19 PM Accepted by SEC EDGAR 06/22/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last)

(First)

(Middle)

2855 SAND HILL RD

(Street)

MENLO PARK

CALIFORNIA

94025

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/19/2026		A⁽¹⁾		8,961	A	$1.66⁽²⁾	102,529	D
Common Stock								4,448,757	I	See Note 3⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.

3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

	/s/ Zachary Bambach, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BDTX director Ali Behbahani report?

Ali Behbahani reported receiving a grant of 8,961 shares of Black Diamond Therapeutics common stock. The award was issued under the non-employee director compensation policy, reflecting his choice to take equity instead of cash for annual board service.

At what price was Ali Behbahani’s BDTX stock grant valued?

The 8,961-share grant to Ali Behbahani was valued using a price of $1.66 per share. This price was based on Black Diamond Therapeutics’ closing common stock price on June 18, 2026, as disclosed in the filing footnotes.

How many BDTX shares does Ali Behbahani hold directly after this grant?

Following the grant, Ali Behbahani directly holds 102,529 shares of Black Diamond Therapeutics common stock. This updated total includes the 8,961 shares awarded as compensation for his annual services as a non-employee director.

What indirect BDTX holdings are associated with Ali Behbahani?

The filing reports 4,448,757 Black Diamond Therapeutics shares indirectly held by New Enterprise Associates 16, L.P. Behbahani is a manager of related general partner entities but disclaims beneficial ownership of portions where he has no pecuniary interest.

Why did Ali Behbahani receive BDTX shares instead of cash?

Behbahani received shares under Black Diamond Therapeutics’ Sixth Amended and Restated Non-Employee Director Compensation Policy. This policy allows non-employee directors to elect common stock in lieu of cash compensation for their annual board service to the company.